BVNKF
Price:
$30.96
Market Cap:
$16.66B
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II ...[Read more]
Industry
Biotechnology
IPO Date
2010-10-15
Stock Exchange
PNK
Ticker
BVNKF
According to Bavarian Nordic A/S’s latest financial reports and current stock price. The company's current Enterprise Value is 15.97B. This represents a change of 37.25% compared to the average of 11.63B of the last 4 quarters.
The mean historical Enterprise Value of Bavarian Nordic A/S over the last ten years is 10.62B. The current 15.97B Enterprise Value has changed 14.93% with respect to the historical average. Over the past ten years (40 quarters), BVNKF's Enterprise Value was at its highest in in the September 2021 quarter at 22.68B. The Enterprise Value was at its lowest in in the September 2014 quarter at 3.74B.
Average
10.62B
Median
9.70B
Minimum
5.48B
Maximum
17.66B
Discovering the peaks and valleys of Bavarian Nordic A/S Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 216.33%
Maximum Annual Enterprise Value = 17.66B
Minimum Annual Increase = -41.14%
Minimum Annual Enterprise Value = 5.48B
Year | Enterprise Value | Change |
---|---|---|
2023 | 12.25B | -22.72% |
2022 | 15.86B | -10.22% |
2021 | 17.66B | 75.04% |
2020 | 10.09B | 20.10% |
2019 | 8.40B | 53.36% |
2018 | 5.48B | -41.14% |
2017 | 9.31B | 8.70% |
2016 | 8.56B | -30.88% |
2015 | 12.39B | 98.07% |
2014 | 6.25B | 216.33% |
The current Enterprise Value of Bavarian Nordic A/S (BVNKF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
15.26B
5-year avg
12.85B
10-year avg
10.62B
Bavarian Nordic A/S’s Enterprise Value is greater than AN2 Therapeutics, Inc. (5.46M), greater than Miromatrix Medical Inc. (90.06M), greater than Inhibikase Therapeutics, Inc. (175.82M), greater than PMV Pharmaceuticals, Inc. (47.10M), greater than Anebulo Pharmaceuticals, Inc. (45.92M), greater than Molecular Partners AG (57.39M), greater than Mineralys Therapeutics, Inc. (604.45M), greater than Pharvaris N.V. (845.60M), greater than PepGen Inc. (174.61M), greater than Edgewise Therapeutics, Inc. (3.13B), greater than Rallybio Corporation (26.17M), greater than Opthea Limited (658.08M), greater than Replimune Group, Inc. (753.03M), greater than Nuvalent, Inc. (6.16B), greater than Ventyx Biosciences, Inc. (123.68M), greater than Ascendis Pharma A/S (6.93B), greater than United Therapeutics Corporation (15.56B), greater than Aura Biosciences, Inc. (487.00M), greater than Axcella Health Inc. (-7493000.00), greater than H-CYTE, Inc. (4.52M), greater than Antibe Therapeutics Inc. (4.53M),
Company | Enterprise Value | Market cap |
---|---|---|
5.46M | $32.23M | |
90.06M | $92.95M | |
175.82M | $178.73M | |
47.10M | $83.46M | |
45.92M | $49.01M | |
57.39M | $247.30M | |
604.45M | $672.30M | |
845.60M | $1.30B | |
174.61M | $221.28M | |
3.13B | $3.16B | |
26.17M | $42.56M | |
658.08M | $629.92M | |
753.03M | $828.74M | |
6.16B | $6.24B | |
123.68M | $153.34M | |
6.93B | $7.10B | |
15.56B | $16.71B | |
487.00M | $498.05M | |
-7493000.00 | $0 | |
4.52M | $624.98K | |
4.53M | $11.45M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Bavarian Nordic A/S using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Bavarian Nordic A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Bavarian Nordic A/S's Enterprise Value?
What is the highest Enterprise Value for Bavarian Nordic A/S (BVNKF)?
What is the 3-year average Enterprise Value for Bavarian Nordic A/S (BVNKF)?
What is the 5-year average Enterprise Value for Bavarian Nordic A/S (BVNKF)?
How does the current Enterprise Value for Bavarian Nordic A/S (BVNKF) compare to its historical average?